Revenue Cycle Management in Molecular Diagnostics
Coverage may depend on the patient’s indication, the ordering clinician’s documentation, the payer’s policy, and whether authorization was secured before testing. When those conditions are handled only after a claim is denied, the laboratory is trying to repair a decision that should have been made upstream.
That is why laboratory revenue cycle management for molecular diagnostics cannot be treated as routine billing with more complicated codes. The financial risk is concentrated in tests that may require substantial laboratory resources, while coverage rules and documentation requirements vary by payer and indication. The work starts before accessioning: with an order that is clinically appropriate, documented, and aligned with the applicable coverage policy.
The Financial Fragility of Molecular Diagnostic Workflows
Molecular testing now supports decisions across oncology, infectious disease, and rare-disease care. Its role in clinical practice has expanded, but the revenue cycle supporting it remains exposed to familiar pressures: high-cost testing, uneven coverage, authorization requirements, and coding rules that are difficult to apply consistently.
A denial is not simply a delayed payment. It can leave a laboratory carrying the cost of reagents, specialized labor, interpretation, and administrative follow-up without knowing whether an appeal will succeed. The financial effect varies by test and payer, but the operational pattern is consistent: the later a coverage problem is discovered, the fewer options remain for preventing it.
Several features make molecular pathology billing challenges particularly difficult:
- The value and cost of individual tests can be substantial. A denied comprehensive panel may have a different effect on the monthly ledger than a denied routine assay. That does not make every molecular denial unrecoverable, but it does make the financial exposure worth tracking by test category.
- Coverage is policy-specific. Medicare coverage may depend on local policy and jurisdiction; commercial plans and Medicare Advantage plans may apply their own requirements. A rule that works for one payer or indication should not be assumed to work for another.
- Coding requires clinical and technical context. Selecting the appropriate CPT code is only part of the task. The claim may also need supporting documentation, diagnosis coding, and, where applicable, additional identifiers such as a Z-code. CPT code compliance for NGS depends on representing the service actually performed, not merely choosing a code associated with a broad category of testing.
- Medical necessity must be evident in the record. A test’s usefulness in general does not establish coverage for every patient or clinical situation. The ordering documentation needs to connect the patient’s circumstances to the test and its intended role in care.
- Payer rules change. Coverage policies, authorization workflows, and reimbursement terms should be monitored as operational inputs rather than treated as static reference material.
A molecular denial is not always a billing problem. Often, it is a workflow problem that first became visible in the billing queue.
These pressures have different causes, so they need different owners. A coding defect calls for a different intervention from missing prior authorization; a repeated medical-necessity denial may point to the test menu, the order, or the supporting record. Grouping every unpaid claim into one denial total makes it harder to see which part of the workflow needs attention.
A useful starting point is to separate financial measures that are often blurred together. A first-pass denial rate, an authorization-related denial count, the proportion of appeals upheld or overturned, and final write-offs describe different stages of the cycle. None, by itself, establishes the share of preventable losses attributable to a particular reason code. Local data is needed to make that judgment.
Decoding High-Complexity Denial Patterns: CO197 and CO55
CO197 and CO55 can signal materially different problems. CO197 generally indicates that prior authorization was required but was not obtained or was not documented. CO55 is associated with a service that the payer considers investigational or not covered under its policy. The exact explanation and next steps depend on the payer’s remittance details and the applicable policy; the code alone is not a complete account of why a claim failed.
| Operational question | CO197 — Prior authorization | CO55 — Investigational or noncovered service |
|---|---|---|
| What may have gone wrong? | Authorization was not obtained, was incomplete, or could not be matched to the claim | The payer determined that the service did not meet its coverage policy for the indication |
| Where should the laboratory look first? | Authorization records, payer requirements, ordering workflow, and claim matching | Coverage policy, patient indication, test selection, and supporting clinical documentation |
| What may support a response? | Proof of authorization, evidence of a payer processing error, or documentation relevant to an exception or appeal | Policy-specific clinical documentation, an applicable coverage basis, or a reasoned appeal where the facts support one |
| What should be reviewed if the pattern recurs? | Whether requirements are visible and assigned before testing | Whether the test is appropriate and supported for the indications in which it is being ordered |
A CO197 denial may be administrative, but that does not mean it is automatically recoverable. An authorization may not have been requested, may have been obtained for a different service, or may not satisfy the payer’s requirements. The laboratory should establish what happened before deciding whether to appeal, correct the claim, or change the workflow.
CO55 requires a different kind of investigation. The team needs to compare the payer’s stated rationale with the test, the patient’s indication, and the documentation submitted. If the claim is unsupported under the relevant policy, a more polished appeal does not solve the underlying problem. If the policy was misapplied or the record contains relevant information that was omitted, an appeal may have a sound basis.
For both codes, the useful question is not simply how often they appear in a national or industry-wide ranking. It is what they reveal about this laboratory’s claims. A code-level review by payer, assay, indication, and ordering location can help distinguish an isolated processing issue from a recurring operational defect.
Coding and documentation belong in the same conversation
Molecular claims often require coordination among the ordering clinician, the laboratory, coding staff, and authorization personnel. A code that accurately describes the laboratory service cannot substitute for a clear clinical indication. Nor can strong clinical documentation correct a code that does not represent the service performed.
An effective internal review therefore looks at the record as a whole: order details, test performed, diagnosis information, authorization, and payer policy. This is particularly important for NGS, where panel scope and reporting can vary. A laboratory should avoid using a single default coding approach when the services or payer requirements differ.
Strategic Utilization Management and Prior Authorization Integrity
Utilization management works best before testing begins. At order entry, the laboratory may still be able to clarify the indication, request missing records, check the payer’s requirements, or contact the ordering provider. After testing, the same questions may be harder to resolve, and the laboratory may already have incurred the cost.
That does not mean every order can be reduced to a simple coverage prompt. Payer policies are not identical, and clinical judgment cannot be replaced by a billing rule. The aim is to make the relevant information visible early enough for people to act on it.
Three practices can make that possible:
1. Add indication-aware support to ordering workflows. Where the LIS or EHR can present payer-specific guidance, prompts should help the ordering team identify missing details or a possible policy mismatch. A prompt should direct users to the relevant requirement, not imply that a software flag alone determines clinical appropriateness or coverage.
2. Assign responsibility for authorization. The laboratory and referring practice should know who requests authorization, who supplies clinical records, and how status is communicated. Work queues need clear ownership and an escalation route when information is missing or a payer response is delayed. The goal is not an arbitrary turnaround promise; it is to prevent an order from moving silently through the system with an unresolved requirement.
3. Review test pathways against actual policy. Reflex protocols should reflect clinical practice and applicable coverage requirements. A protocol should explain why a test follows another test, what clinical question the next step addresses, and what documentation supports that choice. It should be reviewed when payer policies or the laboratory’s test menu change.
Good utilization management does not ask whether a test can be billed after the fact. It asks what needs to be known before the laboratory commits the resources.
Order-entry controls can prevent some avoidable gaps, but they are not a guarantee against denials. A payer may change its requirements, a clinician may need to order testing urgently, or a patient’s circumstances may not fit a standard pathway. Those cases need a documented exception process rather than a workaround that disappears from view.
The operational value of moving checks upstream should be assessed using the laboratory’s own data. Useful measures include the number of orders held for missing information, authorization-related denials by payer, time from order to authorization decision, and the share of cases resolved before testing. Comparing those measures over time can show whether a change is helping; it should not be presented as proof of an industry-wide outcome without supporting evidence.
Optimizing Appeal Workflows to Recover Denied Revenue
An appeal is not a universal remedy for an unpaid claim. It is one option in a sequence that should begin with understanding the denial. Some claims need a corrected submission; others require missing records, a payer inquiry, or a reconsideration. In some cases, the laboratory may conclude that the available facts do not support further appeal.
A disciplined appeal process makes that decision faster and more consistent. It also prevents a team from spending time on a letter when the underlying issue is a recurring failure in ordering, authorization, or coding.
A workable process usually includes four connected functions:
- Denial analysis by payer and test. A dedicated analyst or clearly assigned team member can identify patterns in remittance codes, payer explanations, and affected services. The analysis should distinguish authorization failures from coverage disputes and coding or documentation defects.
- A library of indication-specific materials. Templates can help staff assemble a complete response, but they should not turn into generic letters sent regardless of the case. The appeal must address the payer’s stated reason and the patient’s documented circumstances.
- Clinical escalation when the issue is medical. When a payer’s decision turns on medical necessity or interpretation of policy, a clinician may need to provide context or participate in a peer-to-peer discussion, if the payer offers that route. The billing team should not be expected to invent the clinical rationale.
- A visible aging and follow-up process. Each denial needs an owner, a next action, and a record of relevant deadlines. Reviewing unresolved claims regularly helps the team identify stalled appeals and opportunities to correct an issue before similar claims are submitted.
The response should be grounded in the claim file. Staff should confirm the service performed, the authorization record, the payer’s explanation, the applicable policy, and the clinical documents available. If the appeal relies on a policy interpretation or supporting literature, that material needs to be relevant to the specific question at issue. A stack of attachments is not a substitute for a clear explanation of why the claim meets the payer’s stated requirements.
Appeal outcomes should also feed back into operations. If a payer repeatedly denies the same assay for the same indication, the laboratory should ask whether the ordering pathway is clear, whether the documentation is sufficient, and whether the test is being offered in circumstances the payer does not cover. A recurring denial can be evidence of a process mismatch; it is not automatically evidence that the payer is wrong.
Measure recovery without overstating it
Appeal performance is easy to misread. The number of denials overturned is useful, but it does not show how much was ultimately collected, how many claims were adjusted for unrelated reasons, or whether the appeals were comparable. Laboratories should define their measures clearly: for example, tracking appeal decisions separately from cash collected and write-offs, and segmenting results by payer, denial category, and test.
That level of detail gives managers a basis for choosing where to invest. If authorization defects recur, the response may be upstream workflow changes. If claims are denied for missing documentation, provider education or better order capture may matter more. If a test is consistently outside a payer’s coverage policy, leadership may need to reconsider how it is offered and communicated.
Adapting Laboratory Operations to 2025 Reimbursement Realities
The reimbursement environment is not a single rate change that affects every molecular laboratory in the same way. Medicare schedules, local coverage policies, commercial contracts, and payer utilization rules each shape the amount and likelihood of reimbursement. A laboratory should evaluate the effect of each change against its own payer mix, test volume, cost structure, and contract terms rather than assume a uniform impact across the sector.
That analysis belongs in laboratory operations, not solely in the finance department. Revenue cycle performance depends on decisions about which tests are offered, how orders are accepted, what information is collected, and how staff time is allocated. Clinical lab revenue optimization is therefore not simply a matter of speeding up collections. It includes deciding where process controls reduce avoidable work without obstructing appropriate care.
Three priorities deserve regular management attention:
1. Understand the economics of contracts. In-network status does not by itself show whether a molecular service is sustainable. Leaders should compare contracted terms with the cost of performing the test and the administrative work required to secure payment. Where the terms do not support the service, the issue belongs in contract discussions and service-line planning.
2. Connect operating costs to the revenue cycle. Automation may reduce repetitive work in accessioning, coding support, and claim preparation, but it should be evaluated against actual workflows and error patterns. Faster throughput at the analytical bench will not compensate for preventable authorization gaps or claims that cannot be supported. The goal is to manage both the cost of testing and the cost of getting a valid claim paid.
3. Use denial data as an operational signal. Leaders should review denials, corrections, appeals, and write-offs alongside quality and capacity measures. Trends should be segmented enough to guide action, but not treated as proof of a cause before the underlying records are examined. A rise in one code may reflect a policy change, a documentation problem, a shift in test mix, or a claims-processing issue.
Diagnostic reimbursement policy updates need a reliable route into daily work. When a payer changes a policy, someone should assess which tests and indications are affected, update internal guidance, and communicate the change to staff who place or review orders. A policy stored in a shared folder but absent from the ordering workflow may be technically available while remaining operationally invisible.
The same principle applies to cpt code compliance for ngs. Coding guidance should be maintained with the service description, documentation requirements, and payer-specific considerations that support accurate claims. Changes should be reviewed by people who understand both the test and the billing implications; a code list on its own cannot resolve uncertainty about how a service should be represented.
Molecular diagnostic test utilization management also needs boundaries. Controls should help staff catch missing information and known coverage requirements, not encourage blanket denial of clinically appropriate testing. When coverage is uncertain, the pathway should make that uncertainty explicit and identify who can resolve it. That is more useful than allowing a specimen to proceed with no shared understanding of the financial risk.
The practical measure of a stronger revenue cycle is not a promised reduction in denials or a claim that every appeal will succeed. It is whether the laboratory can identify why claims fail, make timely decisions about which cases to pursue, and change the upstream process when a recurring problem is within its control.
A molecular laboratory that treats revenue cycle management as a back-office task will see problems only after they have become unpaid claims. A laboratory that connects ordering, authorization, clinical documentation, coding, appeals, and contract review can address those problems earlier and make better-informed decisions about the work it accepts. In molecular diagnostics, reimbursement is shaped well before the claim reaches the payer.